Comparative Pharmacology
Head-to-head clinical analysis: BRAFTOVI versus ZELBORAF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRAFTOVI versus ZELBORAF.
BRAFTOVI vs ZELBORAF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRAFTOVI (encorafenib) is a kinase inhibitor that targets BRAF V600E, V600K, and V600D mutant kinases, including BRAF V600E. It inhibits the MAPK/ERK signaling pathway by blocking the phosphorylation of MEK by BRAF, thereby reducing cell proliferation in BRAF-mutant tumors.
Vemurafenib is a selective inhibitor of the BRAF serine-threonine kinase, specifically targeting mutations at codon 600 (BRAF V600E). It blocks the MAPK pathway, reducing cell proliferation in BRAF V600E mutation-positive melanoma cells.
450 mg (6 capsules of 75 mg) orally once daily in combination with binimetinib 45 mg orally twice daily, until disease progression or unacceptable toxicity.
960 mg orally twice daily, approximately 12 hours apart, with or without food.
None Documented
None Documented
Terminal elimination half-life: ~30 hours (range 22–44 h) in patients; supports twice-daily dosing.
Terminal elimination half-life is approximately 52 hours (range 30–70 hours), supporting once-daily dosing and requiring about 10 days to reach steady-state.
Primarily hepatic metabolism, with negligible renal excretion. Approximately 47% of a dose recovered in feces (mainly as metabolites) and 5% in urine.
Renal excretion of unchanged drug is minimal (approximately 2% of the dose). Biliary/fecal elimination is the major route, with about 94% of the dose recovered in feces (primarily as metabolites) and 5% in urine.
Category C
Category C
BRAF Inhibitor
BRAF Inhibitor